An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.
Get full access to this article
View all access options for this article.
References
1.
KumariP, SrivastavaA, BanerjeeR, et al.Functional competence of a partially engaged GPCR-beta-arrestin complex. Nat Commun. 2016; 7:13416.
2.
RasmussenSG, ChoiHJ, FungJJ, et al.Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature. 2011; 469:175–180.
3.
RasmussenSG, DeVreeBT, ZouY, et al.Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature. 2011; 477:549–555.
4.
KenakinT, ChristopoulosA. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013; 12:205–216.
5.
RaehalKM, WalkerJK, BohnLM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005; 314:1195–1201.
6.
DeWireSM, YamashitaDS, RomingerDH, et al.A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013; 344:708–717.
7.
ManglikA, LinH, AryalDK, et al.Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016; 537:185–190.
8.
TurcotteC, BlanchetMR, LavioletteM, et al.The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016; 73:4449–4470.
9.
AshtonJC, GlassM. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2007; 5:73–80.
10.
PalazuelosJ, AguadoT, PazosMR, et al.Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain. 2009; 132:3152–3164.
11.
StempelAV, StumpfA, ZhangHY, et al.Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron. 2016; 90:795–809.
12.
DevaneWA, HanusL, BreuerA, et al.Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258:1946–1949.
13.
MechoulamR, Ben-ShabatS, HanusL, et al.Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995; 50:83–90.
14.
SugiuraT, KondoS, SukagawaA, et al.2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995; 215:89–97.
15.
IversenL, ChapmanV. Cannabinoids: a real prospect for pain relief?. Curr Opin Pharmacol. 2002; 2:50–55.
PertweeRG. Cannabinoids and multiple sclerosis. Pharmacol Ther. 2002; 95:165–174.
18.
HorvathTL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest. 2003; 112:323–326.
19.
Le FollB, GoldbergSR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005; 312:875–883.
20.
LaprairieRB, BagherAM, KellyME, et al.Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of huntington disease. Mol Pharmacol. 2016; 89:364–375.
21.
SegoviaG, MoraF, CrossmanAR, et al.Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord. 2003; 18:138–149.
22.
MukhopadhyayP, BaggelaarM, ErdelyiK, et al.The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016; 173:446–458.
23.
PertweeRG. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem. 2010; 17:1360–1381.
24.
McHughD, PageJ, DunnE, et al.Delta(9)-tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012; 165:2414–2424.
25.
ChuZL, CarrollC, ChenR, et al.N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010; 24:161–170.
26.
Di MarzoV, De PetrocellisL. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem. 2010; 17:1430–1449.
27.
HejaziN, ZhouC, OzM, et al.Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol. 2006; 69:991–997.
28.
MatsudaLA, LolaitSJ, BrownsteinMJ, et al.Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346:561–564.
29.
MunroS, ThomasKL, Abu-ShaarM. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365:61–65.
30.
FelderCC, JoyceKE, BrileyEM, et al.Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995; 48:443–450.
31.
AtwoodBK, Wager-MillerJ, HaskinsC, et al.Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol. 2012; 81:250–263.
32.
SoethoudtM, GretherU, FingerleJ, et al.Cannabinoid CB2 receptor ligand profiling reveals biased signaling and off-target activity: implications for drug discovery. Nat Commun. 2017; 8:13958.
33.
GlassM, NorthupJK. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol. 1999; 56:1362–1369.
34.
CalandraB, PortierM, KerneisA, et al.Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol. 1999; 374:445–455.
35.
GlassM, FelderCC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 1997; 17:5327–5333.
36.
GonzalezB, PazF, FloranL, et al.Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors. J Pharmacol Exp Ther. 2009; 328:822–828.
37.
BashR, RubovitchV, GafniM, et al.The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals. 2003; 12:39–44.
38.
StamerWD, GolightlySF, HosohataY, et al.Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol. 2001; 431:277–286.
39.
ChenXP, YangW, FanY, et al.Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i). Br J Pharmacol. 2010; 161:1817–1834.
40.
LaucknerJE, HilleB, MackieK. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A. 2005; 102:19144–19149.
41.
GarzonJ, de la Torre-MadridE, Rodriguez-MunozM, et al.Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain. 2009; 5:11.
42.
KamatoD, MitraP, DavisF, et al.Gaq proteins: molecular pharmacology and therapeutic potential. Cell Mol Life Sci. 2016; DOI:10.1007/s00018-016-2405-9.
ThomsenAR, PlouffeB, Cahill TJ 3rd, et al. GPCR-G protein-beta-arrestin super-complex mediates sustained G protein signaling. Cell. 2016; 166:907–919.
47.
KeshetY, SegerR. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010; 661:3–38.
48.
Galve-RoperhI, RuedaD, Gomez del PulgarT, et al.Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol. 2002; 62:1385–1392.
49.
SanchezMG, Ruiz-LlorenteL, SanchezAM, et al.Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal., 2003; 15:851–859.
50.
DavisMI, RonesiJ, LovingerDM. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem. 2003; 278:48973–48980.
51.
DerkinderenP, ValjentE, ToutantM, et al.Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci. 2003; 23:2371–2382.
52.
RubovitchV, GafniM, SarneY. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res. 2004; 120:138–144.
53.
HartS, FischerOM, UllrichA. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004; 64:1943–1950.
54.
DaigleTL, KearnCS, MackieK. Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology. 2008; 54:36–44.
55.
Delgado-PerazaF, AhnKH, Nogueras-OrtizC, et al.Mechanisms of biased beta-arrestin-mediated signaling downstream from the cannabinoid 1 receptor. Mol Pharmacol. 2016; 89:618–629.
56.
Nogueras-OrtizC, YudowskiGA. The multiple waves of cannabinoid 1 receptor signaling. Mol Pharmacol. 2016; 90:620–626.
57.
AhnKH, MahmoudMM, KendallDA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 2012; 287:12070–12082.
58.
AhnKH, MahmoudMM, ShimJY, et al.Distinct roles of beta-arrestin 1 and beta-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 2013; 288:9790–9800.
59.
GamageTF, AndersonJC, AboodME. CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling. Cannabis Cannabinoid Res. 2016; 1:272–280.
60.
KhajehaliE, MaloneDT, GlassM, et al.Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol. 2015; 88:368–379.
61.
DerkinderenP, LedentC, ParmentierM, et al.Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem. 2001; 77:957–960.
Molina-HolgadoF, PinteauxE, HeenanL, et al.Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci. 2005; 28:189–194.
64.
GrahamES, BallN, ScotterEL, et al.Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. J Biol Chem. 2006; 281:29085–29095.
65.
HeJC, GomesI, NguyenT, et al.The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem. 2005; 280:33426–33434.
66.
RuedaD, Galve-RoperhI, HaroA, et al.The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol. 2000; 58:814–820.
67.
AdhikaryS, KociedaVP, YenJH, et al.Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood. 2012; 120:3741–3749.
68.
MerighiS, GessiS, VaraniK, et al.Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. Br J Pharmacol. 2012; 165:1773–1788.
69.
BouaboulaM, Poinot-ChazelC, MarchandJ, et al.Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem., 1996; 237:704–711.
70.
CudabackE, MarrsW, MoellerT, et al.The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS One. 2010; 5:e8702.
71.
MooreCA, MilanoSK, BenovicJL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol. 2007; 69:451–482.
72.
HowlettAC, Champion-DorowTM, McMahonLL, et al.The cannabinoid receptor: biochemical and cellular properties in neuroblastoma cells. Pharmacol Biochem Behav. 1991; 40:565–569.
73.
DillJA, HowlettAC. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther. 1988; 244:1157–1163.
74.
Rinaldi-CarmonaM, Le DuigouA, OustricD, et al.Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther. 1998; 287:1038–1047.
CaulfieldMP, BrownDA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992; 106:231–232.
77.
MackieK, DevaneWA, HilleB. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 1993; 44:498–503.
78.
MackieK, HilleB. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A. 1992; 89:3825–3829.
79.
MackieK, LaiY, WestenbroekR, et al.Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995; 15:6552–6561.
80.
JinW, BrownS, RocheJP, et al.Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci. 1999; 19:3773–3780.
81.
RocheJP, BoundsS, BrownS, et al.A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol Pharmacol. 1999; 56:611–618.
82.
DaigleTL, KwokML, MackieK. Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem. 2008; 106:70–82.
83.
GyombolaiP, BorosE, HunyadyL, et al.Differential beta-arrestin2 requirements for constitutive and agonist-induced internalization of the CB1 cannabinoid receptor. Mol Cell Endocrinol. 2013; 372:116–127.
84.
BakshiK, MercierRW, PavlopoulosS. Interaction of a fragment of the cannabinoid CB1 receptor C-terminus with arrestin-2. FEBS Lett. 2007; 581:5009–5016.
85.
SinghSN, BakshiK, MercierRW, et al.Binding between a distal C-terminus fragment of cannabinoid receptor 1 and arrestin-2. Biochemistry. 2011; 50:2223–2234.
86.
LaprairieRB, BagherAM, KellyME, et al.Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014; 289:24845–24862.
87.
BreivogelCS, LambertJM, GerfinS, et al.Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/- mice. Behav Pharmacol. 2008; 19:298–307.
88.
NguyenPT, SchmidCL, RaehalKM, et al.beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry. 2012; 71:714–724.
89.
ConnorM, BagleyEE, ChiengBC, et al.Beta-arrestin-2 knockout prevents development of cellular mu-opioid receptor tolerance but does not affect opioid-withdrawal-related adaptations in single PAG neurons. Br J Pharmacol. 2015; 172:492–500.
90.
DangVC, ChiengB, AzrielY, et al.Cellular morphine tolerance produced by betaarrestin-2-dependent impairment of mu-opioid receptor resensitization. J Neurosci. 2011; 31:7122–7130.
91.
McGuinnessD, MalikzayA, ViscontiR, et al.Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. J Biomol Screen. 2009; 14:49–58.
92.
DhopeshwarkarA, MackieK. Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway. J Pharmacol Exp Ther. 2016; 358:342–351.
93.
GrimseyNL, GrahamES, DragunowM, et al.Cannabinoid receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. Biochem Pharmacol. 2010; 80:1050–1062.
94.
HsiehC, BrownS, DerlethC, et al.Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem. 1999; 73:493–501.
95.
LeterrierC, BonnardD, CarrelD, et al.Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem. 2004; 279:36013–36021.
96.
MartiniL, WaldhoerM, PuschM, et al.Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptor-associated sorting protein GASP1. FASEB J. 2007; 21:802–811.
NieJ, LewisDL. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J Neurosci. 2001; 21:8758–8764.
99.
BrailoiuGC, OpreaTI, ZhaoP, et al.Intracellular cannabinoid type 1 (CB1) receptors are activated by anandamide. J Biol Chem. 2011; 286:29166–29174.
100.
RozenfeldR, DeviLA. Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J. 2008; 22:2311–2322.
101.
BenardG, MassaF, PuenteN, et al.Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci. 2012; 15:558–564.
102.
Hebert-ChatelainE, DesprezT, SerratR, et al.A cannabinoid link between mitochondria and memory. Nature. 2016; 539:555–559.
103.
BouaboulaM, DussossoyD, CasellasP. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem., 1999; 274:20397–20405.
104.
DerocqJM, JbiloO, BouaboulaM, et al.Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem., 2000; 275:15621–15628.
105.
ShoemakerJL, RuckleMB, MayeuxPR, et al.Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther. 2005; 315:828–838.
106.
CarrierEJ, KearnCS, BarkmeierAJ, et al.Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 2004; 65:999–1007.
107.
GrimseyNL, GoodfellowCE, DragunowM, et al.Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta. 2011; 1813:1554–1560.
RaehalKM, SchmidCL, GroerCE, et al.Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011; 63:1001–1019.
BreivogelCS, ChildersSR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther. 2000; 295:328–336.
112.
BreivogelCS, SimLJ, ChildersSR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther. 1997; 282:1632–1642.
113.
SimLJ, SelleyDE, ChildersSR. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci U S A. 1995; 92:7242–7246.
114.
GeorgievaT, DevanathanS, StropovaD, et al.Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol. 2008; 581:19–29.
115.
McAllisterSD, RizviG, Anavi-GofferS, et al.An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem. 2003; 46:5139–5152.
116.
SongZH, BonnerTI. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol. 1996; 49:891–896.
117.
HuaT, VemuriK, PuM, et al.Crystal structure of the human cannabinoid receptor CB1. Cell. 2016; 167:750.e714–762.e714.
118.
ShaoZ, YinJ, ChapmanK, et al.High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 2016; 540:602–606.
119.
BonhausDW, ChangLK, KwanJ, et al.Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther. 1998; 287:884–888.
RedmondWJ, CawstonEE, GrimseyNL, et al.Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. Br J Pharmacol. 2016; 173:115–127.
122.
BisognoT, MelckD, BobrovM, et al.N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000; 351:817–824.
123.
HuangSM, BisognoT, TrevisaniM, et al.An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A. 2002; 99:8400–8405.
MarinelliS, Di MarzoV, FlorenzanoF, et al.N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology. 2007; 32:298–308.
126.
BaillieGL, HorswillJG, Anavi-GofferS, et al.CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol. 2013; 83:322–338.
127.
CawstonEE, ConnorM, Di MarzoV, et al.Distinct temporal fingerprint for cyclic adenosine monophosphate (cAMP) signaling of indole-2-carboxamides as allosteric modulators of the cannabinoid receptors. J Med Chem. 2015; 58:5979–5988.
128.
CawstonEE, RedmondWJ, BreenCM, et al.Real-time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol. 2013; 170:893–907.
129.
ValleeM, VitielloS, BellocchioL, et al.Pregnenolone can protect the brain from cannabis intoxication. Science. 2014; 343:94–98.
130.
HajkovaA, TechlovskaS, DvorakovaM, et al.SGIP1 alters internalization and modulates signaling of activated cannabinoid receptor 1 in a biased manner. Neuropharmacology. 2016; 107:201–214.
131.
GyombolaiP, TothAD, TimarD, et al.Mutations in the ‘DRY’ motif of the CB1 cannabinoid receptor result in biased receptor variants. J Mol Endocrinol. 2015; 54:75–89.
132.
SchuehlyW, ParedesJM, KleyerJ, et al.Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol. 2011; 18:1053–1064.
133.
Klein HerenbrinkC, SykesDA, DonthamsettiP, et al.The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun. 2016; 7:10842.
